Jane Street
PRVB

Jane Street’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Jane Street’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-176,649
Closed -$4.26M – 10008
2023
Q1 		$4.26M Sell
176,649
-85,008
-32% -$1.07M ﹤0.01% 2673
2022
Q4 		$2.77M Buy
261,657
+250,153
+2,174% +$2.02M ﹤0.01% 3351
2022
Q3 		$52K Buy
+11,504
New +$52.4K ﹤0.01% 8914
2022
Q2 		– Sell
-19,661
Closed -$93.2K – 11344
2022
Q1 		$144K Sell
19,661
-40,971
-68% -$245K ﹤0.01% 9264
2021
Q4 		$340K Sell
60,632
-18,178
-23% -$115K ﹤0.01% 7946
2021
Q3 		$504K Sell
78,810
-54,695
-41% -$352K ﹤0.01% 7266
2021
Q2 		$1.13M Buy
133,505
+100,596
+306% +$812K ﹤0.01% 5586
2021
Q1 		$345K Buy
32,909
+14,985
+84% +$211K ﹤0.01% 7482
2020
Q4 		$304K Sell
17,924
-6,133
-25% -$91.9K ﹤0.01% 6400
2020
Q3 		$309K Sell
24,057
-14,982
-38% -$189K ﹤0.01% 5844
2020
Q2 		$551K Sell
39,039
-29,863
-43% -$377K ﹤0.01% 4933
2020
Q1 		$634K Buy
+68,902
New +$888K ﹤0.01% 3361

Other funds holding PRVB

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Jane Street's PRVB Position: Q2 2023 in Review

Jane Street sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 176,649 shares — an estimated $4.26M sold.

Jane Street first reported a position in PRVB in Q1 2020 and held it in 12 quarters. The position peaked at $4.26M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • Jane Street reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Jane Street sold 176,649 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $4.26M.
  • Jane Street first reported a position in Provention Bio, Inc. Common Stock in Q1 2020 and held it in 12 quarters.
  • Jane Street's Provention Bio, Inc. Common Stock position peaked at $4.26M in Q1 2023.
  • 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Jane Street's 13F filing for Q2 2023, filed 14 Aug 2023.